Following progression during first-line EGFR-TKI therapy, Osimertinib yielded significantly better PFS and less adverse effects (grade 3 or higher) than platinum therapy plus pemetrexed in patients with T790M-positive advanced NSCLC, according to a new randomized phase 3 trial.

Source: NEJM.org (Open Access)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s